BioCorRx Provides Business Update for the Full Year Ended 2017
06 avr. 2018 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, April 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Comments on President Donald J. Trump’s Initiative to Stop Opioid Abuse
20 mars 2018 10h40 HE
|
BioCorRx Inc
ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions,...
BioCorRx Provides Update on New Weight Management Program
15 mars 2018 08h08 HE
|
BioCorRx Inc
ANAHEIM, CA, March 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Schedules Business Update Conference Call
01 mars 2018 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, March 01, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
15 févr. 2018 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
12 févr. 2018 09h23 HE
|
BioCorRx Inc
505(b)(2) application plan acceptable per FDA Application will seek dual indications for opioid and alcohol use disorders ANAHEIM, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- BioCorRx...
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
08 févr. 2018 07h30 HE
|
BioCorRx, Inc.
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102
26 janv. 2018 07h30 HE
|
BioCorRx, Inc.
ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic
02 janv. 2018 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
19 déc. 2017 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...